



DFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Bakshi et al.		
Serial No.:	10/788,859	Case No.:	21291Y
Filed:	February 27, 2004		Art Unit: 1626
For:	ACYLATED PIPERAZINE DERIVATIVES AS MELANOCORTIN -4 RECEPTOR AGONISTS		Examiner: Andrew B. Freistein

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NON-COMPLIANT AMENDMENT
AND RESTRICTION REQUIREMENT

Sir:

This is in response to the Office Action of September 27, 2005 pursuant a non-compliant amendment, for which an Amendment is due by October 27, 2005. The Examiner is respectfully requested to consider the accompanying remarks.

Any additional fees associated with this Response may be charged to Merck
Deposit Account No. 13-2755.

Please amend the application as follows:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By [Signature] MERCK & CO., INC.

Date 10/10/2005